Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,629 shares of the medical research company's stock after purchasing an additional 5,769 shares during the quarter. Mawer Investment Management Ltd. owned approximately 0.09% of Charles River Laboratories International worth $8,608,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in Charles River Laboratories International during the fourth quarter worth approximately $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the third quarter worth $59,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Stock Down 5.8 %

CRL stock traded down $8.70 during midday trading on Thursday, hitting $140.58. The company's stock had a trading volume of 269,395 shares, compared to its average volume of 763,099. The firm has a 50-day simple moving average of $163.57 and a 200-day simple moving average of $181.69. The firm has a market capitalization of $7.19 billion, a P/E ratio of 937.20, a PEG ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52-week low of $139.66 and a 52-week high of $264.71.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the company earned $2.46 EPS. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

CRL has been the topic of several analyst reports. Barclays reduced their price target on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 18th. JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Finally, UBS Group reiterated a "neutral" rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average target price of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).